EFEKTIVITAS ANTIVIRUS OSELTAMIVIR PADA SUBJEK COVID-19 DENGAN ATAU TANPA PENYAKIT PENYERTA DI PUSKESMAS ARUT SELATAN – PANGKALAN BUN

  • Soufia Ardiani Program Studi Magister Farmasi Klinis, Fakultas Farmasi, Universitas Surabaya
  • Abdul Rahem Departemen Farmasi Praktis, Fakultas Farmasi, Universitas Airlangga
  • Anita Purnamayanti Laboratorium Klinis Komunitas, Fakultas Farmasi Universitas Surabaya
Keywords: Antivirus, Oseltamivir, Mild covid-19

Abstract

South Arut occupies the highest position with 51.55% of the total COVID-19 cases in Kota Waringin Barat, Central Borneo. The purpose of the study was to determine patient characteristics and analyze the effectiveness of oseltamivir in COVID-19 patients. The research design was an observational study and data collected retrospectively. Inclusion criteria were COVID-19 subjects with or without comorbidities and outpatient treatment at the Arut Selatan, Pangkalan-Bun Health Center who were given Oseltamivir. Parameters of therapeutic effectiveness were measured by the WHO Clinical Progression Scale consisting of 5 levels of clinical condition of patients with a score range of 0 (uninfected) – 10 (died). Data analysis was descriptively grouped according to clinical progression scale scores. The results of the study of 107 subjects were mostly male (56.1%) and aged 26-45 years (34.6%). The clinical results of therapy were 0.9% of subjects recovered with negative swab results (score 0), 98.2% improved (score 1), and 0.9% died (score 10). There were no subjects who needed to be referred to the hospital, Self-quarantine of 8-15 days showed 96 (89.7%) subjects experienced clinical improvement, symptoms free, and swab results were negative. It could be concluded that oseltamivir was effective for mild Covid-19 subjects in South Arut, Pangkalan Bun, Kota Waringin, Central Borneo.

References

Ahmed, S. B., Dumanski, S. M., 2020, Sex, gender and COVID-19: a call to action, Canadian Journal of Public Health; 111(6): 980-983.

Badan Pengawas Obat dan Makanan Republik Indonesia., 2020, Infomatorium Obat COVID-19 di Indonesia, Cetakan pertama, Jakarta.

Chiba S., 2020, Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19, Wien. Klin. Wochenschr; (133): 292–297.

Dinas Komunikasi, Informatika Statistik dan Persandian Kabupaten Kotawaringin Barat., 2021.

Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., 2020, Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med; 382(24): 2327–36.

Hu R., Zhang X., 2020, Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension, Hypertension Research; 43(6), 588-590.

Illah, M. N. N., 2021, Analisis Pengaruh Komorbid, Usia, dan Jenis Kelamin Terhadap Meningkatnya Angka Kematian pada Masa Pandemi Covid-19, Jurnal Sosial Sains; 1(10), 1-228.

McAuley J., Gilbertson B., Trifkovic S., Brown, L.E., McKimm- Breschkin, J., 2019, Influenza virus neuraminidase structure and functions, Frontiers in Microbiology; 10: 39.

Moreno G., Rodríguez A., Sole-Violán J., Martín-Loeches I., Díaz E., Bodí M., Reyes L.F., Gómez J., Guardiola J., Trefler S., 2021, Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia, ERJ Open Res; (7): 00888–2020.

Netter F., CA M., 2003, Atlas of Human Anatomy, Version 3, Icon Learn Syst LLC.

Organization WH., 2020, Coronavirus disease 2019 (COVID-19) Situation Report-70, J Intern Med, Taiwan: 31(2): 61–6.

Perhimpunan Dokter Paru Indonesia., 2020, Pedoman Tatalaksana COVI-19 Edisi 3, Jakarta.

Pilkington V., Pepperrell T., Hill A., 2020, A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?, J Virus Erad; 6(2): 45–51.

Ramatillah, D.L., Isnaini S., 2021, Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. PLoS One; 16(4 April):1–11.

Rusdi, M.S., 2021, Mini Review: Farmakologi pada Corona Virus Disease (Covid-19). Lumbung Farmasi: Jurnal Ilmu Kefarmasian; 2(1), 54-61.

Tan J., Yuan Y., Xu C., Song C., Liu D., Ma D., Gao Q., 2021, A retrospective comparison of drugs against COVID-19, Virus Res; 294 :198-262.

Vakili M., Romano E., Darugar V., Brandán, S.A., 2021, Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations, J Mol Model; 27(12).

Wada T., Shimode K., Hoshiyama T., Takayama Y., Yamaoka K., 2020, Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir, Front Med; 7(May):1–5.

Wahl A., Gralinski LE., Johnson CE., Yao W., Kovarova M., Dinnon, K.H., 2021, SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature; 591(7850): 451–7.

Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., 2020, Clinical characteristics of 138 ospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA; 323 (11): 1061-9.

Ward P., Small I., Smith J., Suter P., Dutkowski R., 2005, Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic, J Antimicrob Chemother; 55(SUPPL. 1).

Whitley, R.J., Hayden, F.G., Reisinger, K.S., Young N., Dutkowski R., Ipe D., Mills, R.G., Ward P., 2021, Oral oseltamivir treatment of influenza in children, Pediatr. Infect. Dis. J; (20): 127–133.

Zhang, X.W., Yap, Y.L., 2004, The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery, J Mol Struct THEOCHEM; 681(1–3):137–41.

Zhang, A.L., Wang, Y., Molina, M.J., 2020, Erratum: Identifying airborne transmission as the dominant route for the spread of COVID-19, Proc Natl Acad Sci, USA; 117(41):25942–3.

Published
2022-10-31
How to Cite
Ardiani, S., Rahem, A., & Purnamayanti, A. (2022). EFEKTIVITAS ANTIVIRUS OSELTAMIVIR PADA SUBJEK COVID-19 DENGAN ATAU TANPA PENYAKIT PENYERTA DI PUSKESMAS ARUT SELATAN – PANGKALAN BUN. Jurnal Ilmiah Ibnu Sina, 7(2), 251-260. https://doi.org/10.36387/jiis.v7i2.879
Section
Artikel

Most read articles by the same author(s)